-
EP3654979
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3654979
| EP3654979 - USE OF WX-UK1 AND ITS PRODRUG, WX-671, FOR THE TREATMENT OF NON-CANCEROUS MEDICAL CONDITIONS [Right-click to bookmark this link] | Status | The application has been withdrawn Status updated on 30.09.2022 Database last updated on 19.07.2024 | |
| Former | Request for examination was made Status updated on 24.04.2020 | ||
| Former | The international publication has been made Status updated on 26.01.2019 | Most recent event Tooltip | 30.09.2022 | Withdrawal of application | published on 02.11.2022 [2022/44] | Applicant(s) | For all designated states Redhill Biopharma Ltd. 21 Ha'arba's Street Tel-Aviv / IL | [2020/22] | Inventor(s) | 01 /
FATHI, Reza 260 Forest Avenue Oradell NJ 07649 / US | 02 /
LEVITT, Mark 18/1 Hatavor Street 73127 Haashmonaim / IL | 03 /
PLASSE, Terry 1725 York Avenue New York NY 10128 / US | 04 /
ABRAMSON, Danielle 18a Forest Place Towaco NJ 07082 / US | [2020/22] | Representative(s) | CMS Cameron McKenna Nabarro Olswang LLP Cannon Place 78 Cannon Street London EC4N 6AF / GB | [2020/22] | Application number, filing date | 18835233.0 | 13.07.2018 | [2020/22] | WO2018IB00881 | Priority number, date | US201762535376P | 21.07.2017 Original published format: US 201762535376 P | US201762574449P | 19.10.2017 Original published format: US 201762574449 P | US201762589734P | 22.11.2017 Original published format: US 201762589734 P | [2020/22] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019016595 | Date: | 24.01.2019 | Language: | EN | [2019/04] | Type: | A1 Application with search report | No.: | EP3654979 | Date: | 27.05.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 24.01.2019 takes the place of the publication of the European patent application. | [2020/22] | Search report(s) | International search report - published on: | US | 24.01.2019 | (Supplementary) European search report - dispatched on: | EP | 15.03.2021 | Classification | IPC: | A61K31/495, C07D295/00, G01N33/68, A61P1/04, A61P1/18, G01N33/573 | [2021/15] | CPC: |
A61K31/495 (EP,KR,US);
A61K9/0053 (KR);
A61P1/04 (EP,KR);
A61P1/18 (EP,KR);
A61P29/00 (KR);
G01N33/573 (EP,US);
G01N33/6893 (KR);
G01N2333/96433 (EP,US);
G01N2333/976 (KR);
G01N2800/52 (EP,KR,US)
(-)
|
| Former IPC [2020/22] | A61K31/4965, C07D295/00, G01N33/68 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/22] | Title | German: | VERWENDUNG VON WX-UK1 UND SEINEM PRODRUG, WX-671, ZUR BEHANDLUNG VON NICHTKREBSARTIGEN ERKRANKUNGEN | [2020/22] | English: | USE OF WX-UK1 AND ITS PRODRUG, WX-671, FOR THE TREATMENT OF NON-CANCEROUS MEDICAL CONDITIONS | [2020/22] | French: | UTILISATION DE WX-UK1 ET DE SON PROMÉDICAMENT, WX-671, POUR LE TRAITEMENT D'AFFECTIONS MÉDICALES NON CANCÉREUSES | [2020/22] | Entry into regional phase | 10.02.2020 | National basic fee paid | 10.02.2020 | Search fee paid | 10.02.2020 | Designation fee(s) paid | 10.02.2020 | Examination fee paid | Examination procedure | 10.02.2020 | Examination requested [2020/22] | 01.10.2021 | Amendment by applicant (claims and/or description) | 26.09.2022 | Application withdrawn by applicant [2022/44] | Fees paid | Renewal fee | 14.07.2020 | Renewal fee patent year 03 | 15.07.2021 | Renewal fee patent year 04 | Penalty fee | Additional fee for renewal fee | 31.07.2022 | 05 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]US5534498 (BRUNCK TERENCE K [US], et al) [Y] 1-15 * col. 10, l. 7-11 *; | [Y]US2004138233 (WILHELM OLAF [DE], et al) [Y] 1-15 * paragraph [0119] *; | [XP] - Oldenberg Emil ET AL, "New potential therapeutic applications of WX-UK1 as a specific and potent inhibitor of human trypsin-2 and human trypsin-3", New Molecular Targets, doi:10.1158/1535-7163.TARG-17-B055Published, (20180101), URL: https://mct.aacrjournals.org/content/17/1_Supplement/B055, (20210302), XP055781163 [XP] 1-15 * the whole document * DOI: http://dx.doi.org/10.1158/1535-7163.TARG-17-B055Published | International search | [Y]US7608623 (SPERL STEFAN [DE], et al) [Y] 1-20 * Col. 5, In 1-4; Col 5, In 35-40; Col 5, In 51-57;Col 6, In 1-6;Col 12, In 47-52; Col 16, In 21 *; | [Y]US2014199709 (GONG HUA [US], et al) [Y] 1-20 * (para [0010]; [0042]; [0068][0252];[0385];[0389] *; | [Y] - FOURCADE et al., "Epithelial Expression and Function of Trypsin-3 in Irritable Bowel Syndrome", Gut, vol. 66, (20170000), pages 1767 - 1778, (20170117), XP055573669 [Y] 17, 18, 20 * abstract; pg. 1768, Col 1, para 1; pg. 1773, Figure 2 * DOI: http://dx.doi.org/10.1136/gutjnl-2016-312094 |